For decades, a small group of plaintiffs lawyers have been pressing claims against companies that made and sold a synthetic estrogen known as diethylstilbestrol, or DES, which was prescribed to millions of pregnant women to ward off premature births and miscarriages from 1948 to 1971.
But after it was linked to a rare vaginal cancer in women whose mothers used it, DES was taken off the market. Studies have since shown that DES didn’t prevent miscarriages, and exposure to the drug in utero has been associated with numerous other illnesses including infertility and breast cancer.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
